开云app官网登录入口网页版-官方正版

#SMO#

285篇内容 | 3673人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2024949, encodeId=ddb62024949ad, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：T-DXd治疗乳腺癌不仅能提高生存，还能改善生活质量（DESTINY-Breast04研究）, objectType=article, longId=739078, objectId=084fe3907869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=084fe3907869, replyNumber=0, likeNumber=107, createdTime=2023-01-12, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=084fe3907869, moduleTitle=ESMO 2022：T-DXd治疗乳腺癌不仅能提高生存，还能改善生活质量（DESTINY-Breast04研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=084fe3907869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024942, encodeId=3e3020249423b, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：创新药物、创新疗法，精彩荟萃, objectType=article, longId=738627, objectId=a5c6e3862703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5c6e3862703, replyNumber=0, likeNumber=84, createdTime=2023-02-07, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5c6e3862703, moduleTitle=ESMO 2022：创新药物、创新疗法，精彩荟萃, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a5c6e3862703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024940, encodeId=70be2024940c6, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！, objectType=article, longId=737089, objectId=21f9e37089c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21f9e37089c5, replyNumber=0, likeNumber=84, createdTime=2023-04-28, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21f9e37089c5, moduleTitle=ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=21f9e37089c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024939, encodeId=4aa2202493935, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, objectType=article, longId=736795, objectId=5afee36795cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5afee36795cd, replyNumber=0, likeNumber=93, createdTime=2022-11-06, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5afee36795cd, moduleTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5afee36795cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=85, createdTime=2022-11-25, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, objectType=article, longId=739183, objectId=460ce39183f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460ce39183f7, replyNumber=0, likeNumber=144, createdTime=2023-03-10, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460ce39183f7, moduleTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=460ce39183f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024943, encodeId=ad562024943d3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, objectType=article, longId=739072, objectId=0c76e39072d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c76e39072d5, replyNumber=0, likeNumber=130, createdTime=2022-09-28, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c76e39072d5, moduleTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c76e39072d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024952, encodeId=c9ea2024952ba, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：CAR-T治疗用于实体瘤研究发布多项重要研究成果！, objectType=article, longId=739081, objectId=ec8be39081d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8be39081d7, replyNumber=0, likeNumber=104, createdTime=2023-08-03, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8be39081d7, moduleTitle=ESMO 2022：CAR-T治疗用于实体瘤研究发布多项重要研究成果！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ec8be39081d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024953, encodeId=43cd202495389, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, objectType=article, longId=739082, objectId=0c30e3908258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c30e3908258, replyNumber=0, likeNumber=140, createdTime=2022-12-19, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c30e3908258, moduleTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c30e3908258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024934, encodeId=23b02024934ff, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302210, objectId=5b43302210bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b43302210bd, replyNumber=0, likeNumber=107, createdTime=2022-05-17, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b43302210bd, moduleTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5b43302210bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024932, encodeId=543d202493283, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, objectType=article, longId=301718, objectId=f3b0301e18e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b0301e18e1, replyNumber=0, likeNumber=88, createdTime=2022-06-04, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b0301e18e1, moduleTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f3b0301e18e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024950, encodeId=366e2024950a5, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, objectType=article, longId=739079, objectId=dbbfe390796d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbbfe390796d, replyNumber=0, likeNumber=103, createdTime=2023-04-24, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbbfe390796d, moduleTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dbbfe390796d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024954, encodeId=1c352024954fa, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022会议精萃, objectType=article, longId=739084, objectId=df47e3908432, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df47e3908432, replyNumber=0, likeNumber=73, createdTime=2022-09-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df47e3908432, moduleTitle=ESMO 2022会议精萃, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=df47e3908432)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024938, encodeId=f68d20249387b, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2022ESMO胃肠肿瘤大会精彩内容盘点！, objectType=article, longId=733758, objectId=1b8ce337587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8ce337587c, replyNumber=0, likeNumber=112, createdTime=2023-06-18, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8ce337587c, moduleTitle=2022ESMO胃肠肿瘤大会精彩内容盘点！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1b8ce337587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024948, encodeId=824f2024948a0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, objectType=article, longId=739077, objectId=6949e390775b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6949e390775b, replyNumber=0, likeNumber=134, createdTime=2023-01-05, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6949e390775b, moduleTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6949e390775b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024931, encodeId=95a3202493167, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=116, createdTime=2022-08-21, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024935, encodeId=0e8a20249355a, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302214, objectId=fba0302214dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fba0302214dc, replyNumber=0, likeNumber=90, createdTime=2022-09-24, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fba0302214dc, moduleTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fba0302214dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024945, encodeId=4a6c2024945fb, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, objectType=article, longId=739074, objectId=6781e3907456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781e3907456, replyNumber=0, likeNumber=79, createdTime=2023-02-25, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781e3907456, moduleTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6781e3907456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024941, encodeId=9db22024941a1, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, objectType=article, longId=739071, objectId=dd97e3907119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd97e3907119, replyNumber=0, likeNumber=96, createdTime=2023-01-14, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd97e3907119, moduleTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dd97e3907119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024944, encodeId=b84c2024944b4, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, objectType=article, longId=739073, objectId=814ce3907329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=814ce3907329, replyNumber=0, likeNumber=107, createdTime=2023-08-27, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=814ce3907329, moduleTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=814ce3907329)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

SMO

2020-05-29

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：T-DXd治疗乳腺癌不仅能提高生存，还能改善生活质量（DESTINY-Breast04研究）

2023-01-12

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：创新药物、创新疗法，精彩荟萃

2023-02-07

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！

2023-04-28

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）

2022-11-06

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2022-11-25

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤

2023-03-10

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）

2022-09-28

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：CAR-T治疗用于实体瘤研究发布多项重要研究成果！

2023-08-03

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）

2022-12-19

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2022-05-17

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）

2022-06-04

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）

2023-04-24

仁医06 (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022会议精萃

2022-09-13

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2022ESMO胃肠肿瘤大会精彩内容盘点！

2023-06-18

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）

2023-01-05

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-08-21

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2022-09-24

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）

2023-02-25

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）

2023-01-14

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当

2023-08-27

科室
- - 订阅+
  - 更多科室
工具
服务